Clinical Trial Update: CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cardio-renal effects of SGLT2 inhibition in kidney transplant recipients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor (unspecified) (SGLT2 inhibitor)

Snippet

Sponsor: Duke University | Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2 | Phase 2 | Status: TERMINATED